STOCK TITAN
  1. Home
  2. News
  3. SLS

SELLAS Life Sciences Group Inc - SLS STOCK NEWS

Welcome to our dedicated news page for SELLAS Life Sciences Group (Ticker: SLS), a resource for investors and traders seeking the latest updates and insights on SELLAS Life Sciences Group.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SELLAS Life Sciences Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SELLAS Life Sciences Group's position in the market.

News
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported positive results from the Phase 2a study of SLS009 in r/r AML, showing a 50% response rate in the selected optimal dose of 30 mg BIW, exceeding the targeted 20%. The company completed enrollment in the Phase 3 REGAL study of Galinpepimut-S in AML, with a potential imminent interim analysis. SLS009 also demonstrated promising results in relapsed/refractory peripheral T-cell lymphoma patients, with top-line data expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
earnings
-
News
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma
Rhea-AI Summary
GenFleet Therapeutics collaborates with BeiGene Switzerland for a combination study in DLBCL patients, aiming to provide innovative therapies for relapsed/refractory cases. The agreement involves a phase Ib/II trial of GFH009 and BRUKINSA® targeting DLBCL, a prevalent form of non-Hodgkin's lymphoma in China. The trial marks the first combination study by a Chinese biotech in this field, with promising results from previous trials of GFH009 in other lymphomas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
clinical trial
-
News
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. announces positive Phase 2a data for SLS009 in AML patients, with a 50% response rate exceeding the targeted 20%. The Phase 3 REGAL Study of GPS in AML has completed enrollment, with an imminent interim analysis. Median OS not reached in Phase 2a study, showcasing strong anti-leukemic activity and favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
clinical trial
News
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (SLS) completes a registered direct offering of common stock and warrants, raising approximately $20 million for research and development activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
offering
-
News
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. provides an update on the Phase 3 REGAL Clinical Trial of GPS in Acute Myeloid Leukemia (AML) and the Phase 2a Clinical Trial of SLS009 in relapsed/refractory AML. The company will host a corporate update call on March 26, 2024, to discuss the latest developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (SLS) has announced a registered direct offering and private placement of common stock and warrants with institutional investors. The Offering includes 13,029,316 shares at $1.535 per share and warrants to purchase the same number of shares at $1.41 per share, expiring in 5.5 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.03%
Tags
offering
News
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (SLS) announced a reorganization of its executive leadership to focus on advancing clinical programs efficiently. Key departures include the Chief Commercial Officer and General Counsel. The company aims to enhance shareholder value through asset development, financial stewardship, and strategic partnerships. Anticipated milestones include interim analysis of Phase 3 REGAL trial and topline data releases for various trials. SELLAS is also strengthening its market access strategies and reimbursement initiatives for potential commercial success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
partnership
-
News
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (SLS) announces positive Phase 1 data for SLS009 in AML patients, achieving complete remission with CDK9 inhibition monotherapy. Key objectives met with durable responses and favorable safety profile. Phase 2a data expected in March and Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
clinical trial
-
News
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. announces a change in the presentation date for data from the acute myeloid leukemia cohort in the Phase 1 study of SLS009 at the 2024 ESH Conference. The presentation will now take place on March 1, 2024, at 12:55 pm CEST in Stockholm, Sweden.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
News
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announces a publication in Oncotarget revealing the underlying mechanisms of action behind the anti-proliferative effects of SLS009, its potent CDK9 small molecule inhibitor, in various hematologic malignancies. The research provides a robust pharmacodynamic and mechanistic foundation for the antiproliferative effects of SLS009 in hematologic cancers and shows its potential in tumor growth inhibition with a dose-dependent induction of apoptosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.48%
Tags
clinical trial
Stock SLS logo
SELLAS Life Sciences Group Inc

Nasdaq:SLS

SLS Rankings

#4389 Ranked by Market Cap
#5312 Ranked by Stock Gains
N/A Ranked by Dividends

SLS Stock Data

75.40M
55.63M
0.5%
10.45%
9.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Camden

About SLS

σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.